-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Comments on the 8th Edition of the TNM Classification of Lung Cancer
By Fabrice Barlesi, MD, PhD, and Eric Vallières, MD, FRCSC An article by Cynthia Kryder and Ramón Rami-Porta in the IASLC Lung Cancer News recently highlighted the innovations of the 8th Edition of the TNM Classification of Lung Cancer. This new classification is more detailed than the 7th edition, as it now contains 11 T…
-
IASLC Workshop in Lung Cancer Clinical Research
By Luis E. Raez, MD The IASLC-Latin American Group (LATAM) successfully organized another “Workshop in Lung Cancer Clinical Research,” as it has done before in other countries like Chile and Peru. Dr. Christian Rolfo and Dr. Luis Corrales chaired the workshop. They were joined by another 10 IASLC faculty from LATAM, including Drs. Luis E.…
-
Robert L. Comis, MD
Clinical Trial Leader and Patient Champion Passes Away at 71 Robert L. Comis, MD, passed away suddenly in his home on May 10, 2017. He was 71. A leader in international oncology research since 1977, Dr. Comis was a champion of patient access to clinical studies in cancer, spearheading initiatives to raise awareness about the…
-
World No-Tobacco Day 2017: Women Against Lung Cancer in Europe’s European Union Event on Primary Prevention
By Gian Piero Bandelli, MD, Federica Ferraresi, WALCE Advocate, and Silvia Novello, MD, PhD On the occasion of World No Tobacco Day 2017, Women Against Lung Cancer in Europe (WALCE), in partnership with European Network for Smoking and Tobacco Prevention (ENSP), European Lung Foundation (ELF), European Respiratory Society (ERS), Fondazione Insieme Contro il Cancro, and…
-
Changing Treatment Paradigm for ALK-Positive Lung Cancer
By Cynthia L. Kryder, MS, CCC-Sp Rearrangements in the anaplastic lymphoma kinase (ALK) gene occur in approximately 2% to 7% of patients with advanced non-small cell lung cancer (NSCLC).1 For patients with advanced ALK-positive NSCLC, the current firstline standard of care is crizotinib, a MET tyrosine kinase inhibitor (TKI) with activity in ALK-rearranged NSCLC. It…
-
Prof. Nir Peled, MD, PhD, FCCP
Posted: June 2017 Prof. Nir Peled was elected Head of the European Respiratory Society Thoracic Oncology Assembly. Prof. Peled is a pulmonologist and medical oncologist. He is the head of the Thoracic Cancer Unit and The Center of Precision Cancer Care at Davidoff Cancer Center, and Associate Professor at the Sackler Faculty of Medicine, Tel Aviv…
-
Steven M. Keller, MD
Posted: June 2017 Steven M. Keller has been appointed Senior Principal Scientist, Oncology Clinical Research, at Merck, Kenilworth, US. Previous to this appointment, Dr. Keller was Director, Thoracic Surgery, Weiler Hospital; Professor of Cardiothoracic Surgery at the Albert Einstein College of Medicine; and faculty member, Montefiore Lung Cancer Preceptorship Program, New York, US.
-
Robert J. Cerfolio, MD, MBA
Posted: June 2017 Robert J. Cerfolio has been appointed chief of clinical thoracic surgery at NYU Langone Medical Center, New York, US. Dr. Cerfolio also will serve as director of the new Lung Cancer Center at NYU Langone’s Perlmutter Cancer Center. Prior to his appointment, Dr. Cerfolio served as chief of the section of thoracic oncology…
-
Role of Molecular Testing for AHCP Caring for Patients with NSCLC
Posted: June 2017 By Kimberly Rohan, ANP-BC Treatment for patients with NSCLC today has become increasingly personalized over the past few years. It is paramount to be able to test a patient’s tumor for mutations and other molecular aberrations to provide the most effective care. In 2004, the observation was made that somatic mutations in…
-
ELCC 2017 Unveils New Research Regarding Screening, Immunotherapy, Treatment Planning, and More
Posted: June 2017 By Keightley Amen, BA, ELS In early May, at the seventh annual European Lung Cancer Conference (ELCC) in Geneva, Switzerland, multidisciplinary lung cancer professionals gathered to learn about the latest research advances in the field. Men Require More Frequent Screening for Lung Cancer A study presented at ELCC retrospectively reviewed patients who…